Revenue of $5.3 billion increased 4.5% as reported, 6.0% currency-neutral and 0.9% organic GAAP and adjusted diluted EPS of $1.07 and $3.35, respectively Company updates full-year fiscal 2025 guidance and provides estimated tariff impactFRANKLIN LAKES, N.J., May 1, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced results for its fiscal 2025 second quarter, which ended March 31, 2025."Amid a difficult operating environment impa ...

Core Insights - BD has received FDA 510(k) clearance for the Phasix™ ST Umbilical Hernia Patch, marking it as the first fully absorbable hernia patch specifically for umbilical hernias [1][2] - The patch is made from Poly-4-hydroxybutyrate (P4HB) and incorporates a hydrogel barrier based on Sepra® Technology, providing a unique solution for umbilical hernia repair [2][3] - The product is designed to be deployed using the same surgical techniques as traditional permanent mesh patches, enhancing its usability for surgeons [2][3] Product Features - Phasix™ ST Umbilical Hernia Patch combines the features of the Ventralex™ ST Hernia Patch with the bioabsorbable nature of Phasix™ Mesh, offering a reliable alternative to permanent mesh [2][3] - The patch is available in three sizes, accommodating a wide range of umbilical soft tissue defects and allowing for adequate overlap as per surgeon preferences [3] Market Position and Demand - A recent survey indicates that 60% of patients prefer non-permanent mesh options for hernia repair, and over 70% of surgeons are willing to accommodate these preferences [3] - The Phasix™ Mesh product line has over 385,000 implants globally and has been validated through more than 85 clinical publications, demonstrating proven clinical outcomes [3]